hADM (Re2O · CellREDM): how far has this material been established?

Look into boosters and you meet a great many comparison tables that do no more than list names. The fork that actually matters is a single one. Does it tell the skin to do something, or does it give the skin the thing directly?

GOURI (liquid PCL), Radiesse · DCLASSY (CaHA) and JUVELOOK (PDLLA) are all on the telling side. A substance the body reads as foreign goes in, and collagen is made inside that response. Rejuran (PN) is on the side of changing the environment rather than provoking it, and BYRYZN (cross-linked HA) is on the side of putting a water-holding substance in directly.

hADM does not sit neatly in any of these. It puts the structural material of skin in whole — type I · type III collagen, elastin, glycosaminoglycans, and glycoproteins such as fibronectin and laminin. These are exactly what falls away with age, and the idea behind hADM is to put them back.

The product-by-product detail is written up separately in our Re2O and CellREDM references. This piece looks only at what those two pages do not cover — what this idea actually rests on.

Material describing hADM often carries the sentence “it does not simply fill; it becomes a scaffold for cells to grow into”. It reads pleasantly enough to pass over, but this sentence has actually been tested.

One study injected injectable hADM under the dorsal skin of 50 mice and took tissue at 2 · 4 · 8 · 12 · 24 weeks. The comparator was the same material in sheet form, that is, the form laid down in the operating theatre.

A thin capsule is a finding worth reading. When the body meets a substance it cannot accept, it throws a fibrous membrane around it and shuts it away. The thicker that membrane, the larger the foreign-body response; the thinner it is, the more the material has been taken into the tissue.

Another study put four materials into nude mice and, at 8 weeks, measured volume and examined the tissue. Micronised hADM retained 113.5% of its volume at 8 weeks, against 85.1% for hyaluronic acid and 17.7% for a collagen-and-PMMA mixture. The tissue showed clear fibrous infiltration and new vessels. The reading of why more remained than went in is that the body built tissue of its own in the same place.

Hyaluronic acid does not give findings like these. Hyaluronic acid is a substance that takes up the space and then breaks down and goes, leaving nothing behind in that place. This is where “filling” and “making room” part company.

All of this, though, is animal work. A study taking human facial skin and confirming the same thing is one we could not find. Whether what was observed under the dorsal skin of a mouse happens the same way in human facial dermis is ground that is still unconfirmed.

Re2O has a split-face double-blind randomised trial carried out at Severance Hospital, Yonsei University. Re2O went into one side of the face and hyaluronic acid into the other, with measurements over 20 weeks at baseline and at 1 · 4 · 8 · 12 · 16 · 20 weeks.

It is probably better to say first why this design is worth something. The commonest trap in judging a cosmetic procedure is that conditions differ from person to person. Age, skin thickness, sun exposure, the season of that year, that person’s habits — all of it mixes into the result. A split-face design compares the left and the right of the same person, so those variables cancel each other out. On top of that it was double-blind, so neither the operator nor the assessor knew which side was which.

The results: skin density, skin volume, wrinkle depth, pore area, hydration, transepidermal water loss, elasticity and pigmented area came out significantly better on the Re2O side (p<0.05 at each timepoint). There were no serious adverse events, and transient erythema and mild swelling settled on their own.

To add the honest note from a clinic that holds ten boosters, not many boosters have a controlled human trial of their own product. For the three lifting devices we use we could not find a published clinical trial of the device itself, and JUVELOOK has only uncontrolled observational work. On that count, this trial of Re2O’s is an uncommon piece of material.

The scale is small. Twenty participants, 20 weeks of follow-up. A size like that is properly read as exploratory, and it has almost no power to pick up an adverse event that occurs rarely. And most of the endpoints are numbers read off instruments — density, volume, hydration and the like; assessment by human eye was a secondary endpoint.

Within the range we were able to check, there are two human studies of injectable hADM.

The second row is the largest and methodologically firmest material to have appeared so far. Micronised ADM was placed in the nasolabial folds and compared against a cross-linked collagen filler, and the wrinkle-improvement rate did not fall behind the filler: 88.4% against 85.4% at 3 months, and 70.9% against 69.7% at 6 months. That said, early local reactions (pain · swelling · heat) appeared more often on the ADM side; they were mild and settled within a week.

This study cannot be read straight across onto the products sold in Korea. The product is different, and so are the site and the manner of injection — filling one nasolabial fold and the Korean skin-booster practice of spreading a thin dose through the dermis are not the same procedure.

About the third row we will put the wording precisely. Not “there is no research”, but “we could not find any”. The manufacturer’s press material does not cite clinical data either. The reason we hold CellREDM is not clinical material but that its particles are finer, which makes it easier to use in thin areas, and we have written that same thing into our CellREDM reference.

There is a sentence that turns up in almost every account of hADM: “a material long used in burn care and breast reconstruction”. Our own Re2O reference says as much, and it is true. It is worth separating out, though, what that sentence guarantees and what it does not.

What it guarantees — what this material is, and how the body handles it, have been studied for a long time. In the treatment of gingival recession alone there are 24 randomised controlled trials covering 587 patients. Which is to say the identity of the material is not in doubt.

What it does not guarantee — that body of evidence does not mean “fewer complications”. In an analysis pooling 16 breast-reconstruction studies and 4,876 cases, the side using ADM had more seroma · infection · reconstruction failure, not fewer (odds ratios 3.9 · 2.7 · 3.0 respectively). A widely used, well-studied material and a safe material are two different statements.

And there is something more important still. All of that evidence is about laying a sheet down surgically. A review that went through 170 clinical studies in burns · wound care from 1999 to 2020 contains not one line about micronised or injectable forms. The form is different, the place it goes is different, the amount is different. Micronising is also a manipulation that greatly increases surface area.

To put it together: “a material long used in surgery” is a sentence that explains what hADM is, not a sentence that stands in as a guarantee of the efficacy or safety of injectable hADM. The evidence for the injectable form is what the sections above set out — animal histology and two human studies — and that is all of it. We write this distinction out because the sentence is so often used as a guarantee rather than as an explanation.

hADM is not a medical device. Because it comes from a person, it falls under the Act on the Safety and Management of Human Tissue. A tissue bank must be licensed by the Commissioner of the Ministry of Food and Drug Safety (MFDS) (Article 13), and imports must meet safety standards as well (Article 17). Distribution and transplantation are prohibited where the donor had a transmissible infection such as hepatitis B · C, HIV or syphilis, or where the cause of death is unknown.

Safety is managed in three layers — donor screening and serological testing, viral inactivation during processing, and the decellularisation step that removes the cellular antigens and the DNA behind immune reactions. It is this structure that is taken to keep the risk of rejection low even though the tissue comes from another person.

There is one conclusion that follows from this, though. Because human tissue is not subject to medical-device product licensing, there is no obligation of prior product-level approval or of submitting clinical trial data. Hyaluronic acid · PDLLA · collagen boosters are licensed as medical devices and their adverse events are tallied in a public database; hADM has no such channel. How to read the numbers is set out in “Is this product approved by the MFDS?” — having no licence number and being illegal are two different statements.

That gap is being closed at the moment. In August 2026 the MFDS put an amendment to the Rules on the Safety of Human Tissue out for public comment. The aim is to finish it within 2026.

On that last row, let us set down where Miso Clinic stands. We have done it that way from the start. Both our Re2O and CellREDM references state in their opening paragraph that the raw material is donated human skin, and we always explain it in the consulting room before treatment. If the human origin of the material is uncomfortable for you, the plan can be built quite differently, out of families that are not of human origin — that is exactly why we hold several boosters. When the rule is finalised and the disclosure becomes a duty, nothing changes for us.

There are open questions raised in the academic community as well. One is that residue limits for the detergents used in decellularisation have not yet been set for injectable preparations; another is that the response to material whose surface area has been increased by micronising has not been sufficiently verified; and a classification argument is running over whether powdering · enzymatic treatment goes beyond the scope of ‘minimal manipulation’. On the other side is the view that it has been used clinically without trouble since around 2015 and that current oversight is sufficient. It is not our place to say which side is right. What we do think is that the bare fact that an unsettled discussion is under way is worth knowing before you choose.

Here, as they stand, are the things we could not confirm in writing this.

• Histology in human facial skin — the observation that cells move in and vessels form comes from animals. A study taking human facial skin and confirming it is one we could not find.
• The course beyond 20 weeks · 6 months — whether the material placed is eventually replaced by the person’s own tissue, absorbed, or left in place has no answer yet. Which is why our own product references do not carry a phrase like “lasts for so many months”.
• A standard number of sessions — various figures circulate online, but a protocol settled by research is one we could not confirm.
• Published clinical work on CellREDM — we could not find any.
• Repeat treatment and combination with other products — the absence of data here is a point raised within the Korean academic community as well.
• Material comparing Re2O and CellREDM head to head — it does not exist. There is no basis on which to say either is better.
• The funding source of the Re2O trial — whether it was manufacturer-sponsored is something we could not confirm. It is an item to weigh when reading the results.

Reduced to three sentences, it goes like this.

One. hADM is the one branch among boosters that puts the material itself in, and the “it becomes a scaffold” account was actually observed in animal histology — cells moved in, vessels formed, and the membrane that marks a foreign-body response came out thin.

Two. In people, Re2O has a split-face double-blind randomised trial. At 20 people · 20 weeks the scale is small, but the design compares the left and the right of the same person, which makes the result worth reading. For CellREDM we could not find published clinical work.

Three. The sentence “a material long used in surgery” is an explanation, not a guarantee. And in August 2026 the MFDS put out for public comment a rule change aimed at cosmetic use.

If we were to write down one criterion that helps in choosing — hADM is the material that answers the problem of ‘my skin has thinned and lost density’ most directly. If the main problem is lost volume or a slackened contour, another family is the right one. Sorting out which is the main problem is half of the consultation.

Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Every study cited above is given together with its design, its size and the limitations the authors themselves recorded, and where we could not find data, we have said that we could not find any.